Clinical Trial Update: Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neratinib (HKI-272) in subjects with advanced breast cancer has completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms

Drugs mentioned

• neratinib (neratinib)

Snippet

Sponsor: Puma Biotechnology, Inc. | Conditions: Breast Neoplasms, Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2017-09-13